arbormed.com

About the project

ARBORMED Corporation positions itself as a specialized pharmaceutical business created with a clear mission. The company operates in two key vectors: developing new drugs for rare and intractable diseases, as well as entering the US market with complex generic products.

This is not just a generic manufacturer, but a company striving to become a bridge between development and the real market. Their approach involves creating a diversified portfolio, where innovative drugs coexist with complex analogues of existing drugs.

Main directions

The company's activities are divided into several strategic blocks, each of which has its own characteristics:

• Development of new drugs (New drugs). Focus has shifted to rare diseases. The projects are at the mid-preclinical stage, which means the transition from laboratory research to more serious trials. The goal is to create best in class therapies with validated targets.
• Complex Generics. The direction is aimed at penetrating the American market. Here the company does not simply copy formulas, but solves technical problems in creating complex analogues.
• Partnership. The strategy includes working with strategic partners. The condition for success is the presence of a common goal and vision among all participants in the process.

There are already specific candidates in the portfolio. For example, ARBM-101, a drug being developed to treat Wilson's disease, received positive regulatory approval. Projects ARBM-201 and ARBM-301 are also mentioned, although details of their development are limited in the public domain.

Features of the site

Information structure arbormed. com reflects the corporate nature of the business. The site contains sections on the company's history, leadership team, and hiring culture. Particular attention is paid to news: data on attracting investments (for example, a $1.6 million round) and the status of FDA approval of drugs is published here.

Interestingly, the company operates under two co-CEOs - Kyojin Park and Wonbin Lim. This is a management model that is atypical for many structures and emphasizes flexibility in decision making.

The site also serves as a recruiting platform. The CAREERS section invites talent who shares the organization’s values, which indicates a desire to build a team from scratch or actively expand it.

Contact information

The company has a physical presence in two countries, which confirms its international status:

• South Korea (headquarters):Alpha Tower 202, Pangyoyeok-ro 180, Bundang-gu, Seongnam-si, Gyeonggi-do 13524. Telephone: 031-8039-6219.
• USA (branch of ARBORMED Pharmaceuticals Inc.):611 Gateway Boulevard Suite 120, San Francisco, California 94080. Phone: +1 650-861-1353.

For communication, specialized email addresses are used, tied to regions or specific employees.

• charset: utf-8
• property: og:type content: website
• property: og:title content: ARBORMED
• property: og:description content: ㈜아보메드는 희귀난치성 질환 중심의 신약개발과 complex generic 의약품의 미국 시장 진입 가교 역할을 목표로 설립된 전문 기업입니다.
• name: description content: ㈜아보메드는 희귀난치성 질환 중심의 신약개발과 complex generic 의약품의 미국 시장 진입 가교 역할을 목표로 설립된 전문 기업입니다.
• name: viewport content: width=device-width,initial-scale=1.0,minimum-scale=0,maximum-scale=10
• equiv: imagetoolbar content: no
• equiv: X-UA-Compatible content: IE=Edge

• http://arbormed.com/en/
• Overview
• Who we are
• History
• Contact
• New drug
• ARBM-101
• ARBM-201
• ARBM-301
• Strategies
• Complex Generic
• News
• Notice
• Talents
• Recruit
• Our Culture
• ESG Management
• ESG Strategy
• ESG Disclosure
• KOR
• ENG
• http://arbormed.com/#section-page1
• http://arbormed.com/#section-page2
• http://arbormed.com/#section-page3
• http://arbormed.com/#section-page4
• http://arbormed.com/#section-page5
• http://arbormed.com/#section-page6
• ARBORMED Pharmaceuticals Inc.
• http://arbormed.com/sub02_02.php
• http://arbormed.com/sub02_03.php
• http://arbormed.com/sub02_04.php
• https://arbormed.com/en/bbs/board.php?bo_table=partner
• 한국유나이티드제약(주)
• iCure 아이큐어
• University of Wisconsin
• QuBEST BIO
• Charles River(Laboratories)
• INDpharm
• KAIST
• 가천대학교
• intertek
• HelmholtzZentrum munchen
• UNIVERSITY OF MICHIGAN
• LOWA STATE UNIVERSITY
• 연세대학교
• ILDONG 일동제약
• WuXi AppTec
• Research Partner NDIC
• AIMS BioScience
• INA
• https://arbormed.com/en/bbs/board.php?bo_table=news_en&wr_id=2765
• Patient Demand Driven by Side Effects …
• Arbormed and Penmix Apply for U.S. FDA…
• ArborMed Enters European Licensing Agr…

            Domain Name: ARBORMED.COM
Registrar: Gabia, Inc.
Domain Status: active
Creation Date: 2016-02-08T19:28:36Z
Registry Expiry Date: 2027-02-08T19:28:36Z
Updated Date: 2026-01-29T01:59:05Z
Name Server: NS1.CAFE24.CO.KR
Name Server: NS1.CAFE24.COM
Name Server: NS2.CAFE24.CO.KR
Name Server: NS2.CAFE24.COM
REGISTRAR Contact: Gabia, Inc.
>>> Last update of RDAP database: 2026-03-17T22:15:44Z         

			User-agent: Yeti
Allow:/
        

Technical SEO

On-Page SEO

Content and UX